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THE PRODUCTION by human tumours
of a variety of substances, widely known
today as "tumour markers", is now well
recognized and could, at least in theory,
provide a biochemical index to facilitate
cancer detection and treatment. Unfortu-
nately, no tumour marker has yet been
found which is specific for malignant
disease, and their value is minimal in
the detection and differential diagnosis
of primary localized cancers (Neville &
Cooper, 1976). However, some markers
have proved to be of value as aids in the
detection ofmetastases and therapy moni-
toring. The best examples are o-foeto-
protein (AFP) and germ-cell tumours and
hepatomas, the carcinoembryonic antigen
(CEA) and colorectal carcinomas, human
chorionic gonadotrophin (hCG) and
choriocarcinoma and a variety ofhormones
in association with the appropriate endo-
crine tumours (Laurence & Neville,
1981).
Tumour markers for breast cancer
have been the subject of considerable
research, and many claims have been
made for at least 40 different markers in
this disease. At present, the best markers
appear to be the plasma levels of CEA,
alkaline phosphatase and y-glutamyl
transpeptidase (Coombes et al., 1980a,
b) but even these are of little clinical rele-
vance to the earlier detection of primary
and/or metastatic disease.
Human placental lactogen (hPL) and
pregnancy-specific 3i-glycoprotein (SP1)
are placental proteins normally present
in the sera of pregnant women. Their
"ectopic" secretion by breast tumours
has been claimed. hPL has been found
in the sera of breast-cancer patients
(Gaspard et al., 1973; Sheth et al., 1977)
and in breast-carcinoma tissue (Horne
et al., 1976) while SP1 has been detected
in sera (Searle et al., 1978; Wiirz, 1979;
Grudzinskas et al., 1980; Bremner et al.,
1981), breast-tumour tissue (Horne et al.,
1976; Wurz, 1979; Inaba et al., 1980;
Bremner et al., 1981) and in the culture
medium in which a breast-cancer cell
line has been grown (Horne et al., 1979).
Perhaps the most potentially important
study has been that of Horne et al. (1976)
in which tumours with a positive immuno-
peroxidase staining for hPL and SP1 were
stated to have a poorer prognosis than
those not expressing them. No other
similar study has been published subse-
quently and no other relationship has
been found, or looked for, between raised
serum hPL and/or SP1 levels and clinical
or pathological factors.
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inX this paper we report our results of
estimating by radioimmunoassay hPL and
SP1, in the sera of patients w%ith variouis
breast diseases.
Patients. The study consisted of 262
patients admitted to the Breast Unit ofthe
Royal Marsden Hospital, London, for in-
vestigation and treatment. Inaddition to a
clinical examination, xeroradiography and
aspiration cytology, the following in-
vestigations were made: (i) full blood
count, erythrocyte sedimentation rate
(ESR), blood group, liver-function tests,
serum immunoglobulins, urea, electrolytes,
calcium, phosphate and urate; (ii) chest
X-ray, grey-scale liver ultrasound and/or
liver scan, technetium polyphosphate bone
scan, after which any suspicious areas
were examined by partial or total skeletal
survey; and (iii) 24 h urinary hydroxy-
proline/creatinine ratio. In patients with
presumed benign lesions, only a full
blood count and ESR were made.
The patients fall into 5 groups, namely:
local/regional group 117 patients with
carcinoma of the breast with or without
tumnour involvement of the axillary
lvmph nodes: locally recurrent, group
9 patients with local recurrence in the
residual breast, scar or axilla: disease-
free group 4 patients with previous
surgically treated breast cancers; dis-
seminated group 10 patients with overt
metastases: and benign group-22 patients
with benign disease.
Blood samples. Serum samples from
patients with operable breast cancer, local
recurrences and benign diseases were taken
immediately before surgery.Samplescollec-
ted from patients receiving chemotherapy
were obtained as many days as possible
after the preceding drug dose, and before
a new drug dose. Blood was allowed to
clot for 1-2 h at, room temperature before
separation. The bottles were then centi-i-
fuged at 1000 g for 15 mnin, serum wras
aliquoted and stored at - 20'C until
assay.
hPL radioimmuinoassay. Lev-els of hPL
were determined by a double-antibody
radioimmunoassav. hPL, as standard and
for iodinationi, was puirchase(d from Nutri-
tional Biochemicals, Cleveland, Ohio,
U.S.A. 1251-sodium iodide (IMS-30) was
obtained from the Radio-chemical Centre,
Amersham, and antiserum to hPL was
raised in New Zealand white rabbits at
the Institute of Obstetrics and Gynae-
cology, Chelsea Hospital for Women,
London, with hPL (Lot No. 717340)
suipplied by Dr C. B. Breuer, Lederle
Laboratories, New York, U.S.A. Normal
human male serum was added to all
blank and standard tubes, in an equal
volume to the sample to be assayed,
and an equal volume of assay buffer was
added to every tube containing samples
to keep the total volume constant in
each tube. To obtain greater sensitivity
the antiserum was diluted 1:400,000 in
the buffer containing nornmal rabbit
serum (1: 400 v/v) and pre-inicubated with
the samples for 72 h. 125I-hPL was then
added and incubation was continued
for 24 h, after which the anti-rabbit-y-
globulin was added and the tubes were
incubated for a fuirther 24 h. The sensi-
tivity limit of the assay was 0-2 pug/l.
The intra-assay and the inter-assay co-
efficients of variation wxNere 87%o and
1220/, respectively.
SP, readioimn maunoassay. Estinmations of
SP, were performed using a polyethylene
glycol precipitation radioimmunoassay
described elsewhere (Grudzinskas et al.,
1977). The minimuim detection limit was
20 ,tg/l. The intra-assay andI the inter-
assav coefficients ofvariation were 400 and
90o, respectively. In both assays standards
and samples were run in triplicate.
Estimations of hPL were performed
in all 262 patients. SPi was measured in
in only 193 patients: 99 of the local/
regional group, 5 of the locally recurrent
group and 89 of the disseminated group.
No patient, had an hPL or a SP1 level
above the sensitivitv limits of the res-
p)ective assayvs.
There is a contiinuing need to derive
markers demonstrable in breast tumours
or in the sera of breast-cancer patients
wNhich may give a gutide as to future prog-
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inosis as well as providing indices to moni-
tor the course of the disease. The demon-
stration of placental protein in breast
tumours by Horne et al. (1976) appeared
to be of importance. Our study, however,
has failed to detect raised levels in the
blood of breast cancer patients. Doubts,
therefore, about the prognostic value of
such pregnancy proteins in breast cancer
must noNw be expressed.
The evidence reported by Gaspard
et al. (1973) and Horne et ai. (1976) to
support hPL production by breast tum-
ours has been based on different methods
from that used in the present work. The
most directly relevant study to our own
has been reported by Sheth et al. (1977)
who used a less sensitive double-antibody
radioimmunoassay (1-2 pg/l). They foundl
slightly raised levels in the 3-5 jug/l
range. However, there was nio correlation
between the raised levels and any clinical
or pathological parameters. The sensi-
tivity of the present hPL radioimmuno-
assay is similar to that of Weintraub &
Rosen (1971). They studied sera from 295
patients with a variety of non-trophoblast
malignant tumours, and raised hPL values
were found in only a minority of patients.
In a personal communication, Rosen (1979)
has confirmed that he never found raised
serum hPL in patients with breast cancer.
OuI SP1 results are supported by
Engvall et al. (Unpub.) who have been
unable to confirm the reported ectopic
production of SP1 in. vivo by a variety
of non-trophoblast ttumours, including
breast. Although more sensitive SP1
radioimmunoassavs have been used by
other groups of investigators in studies
of breast-cancer patients (Searle et al.,
1978: Wurz, 1979; Grudzinskas etal., 1980:
Bremner et al., 1981) the incidence of the
reported raise(d SP1 levels has been from
2 4% tup to 33.7%0. Few patients had
values above than the limit of sensitivity
of our present SP1 radioimmunoassav.
Despite the evidence which has been
produced to support SP1 secretion by
breast tumours, controversial points have
been raised and fturther clarification is
needed. The detection of small amounts
of circulating SP, in normal healthy
subjects and in patients with non-malig-
nant diseases has been reported (Searle
et al., 1978: Wiirz, 1979: Grudzinskas
et al., 1980; Bremner et al., 1981). Wurz
has found slightly raised values in 5366%
of healthy men and non-pregnant women.
Wurz (1 979) has shown in some patients
that SP1 levels fell both after the surgical
removal of the tumour and following
chemotherapy for recurrent breast cancer.
Although she detected SP, in tumour-
tissue homogenates, she was unable to
demonstrate a correlation between SP1
in serum and tumour-tissue homogenates
from the same patient.
Conflicting results have been found
in patients with breast carcinoma as to
the nature of the circulating material
when tested for parallelism with reference
preparations. Wurz (1979) and Grudzins-
kas et al. (1980) have found immuno-
chemical similarity. Searle et al. (1978)
also found similarity in patients with
malignant teratomas but not with breast
cancer. For this reason, they have pointed
out that SP1 results obtained in patients
with non-trophoblast tumours must be
interpreted with caution.
Whilst the presence of SP1 was de-
inionstrated in the medium in which a
breast cancer cell line has been grown
(Horne et al., 1979) other workers have
found that fibroblast cell lines in culture
also produce immunoreactive SP1 (Rosen
et al., Unpub.; Engvall et al., Unpub.).
Nevertheless the study of localization of
SP1 by immunocytochemistry by Inaba
et al. (1980) compares favourably with
that by [lorne et al. (1976): 526°/ and
600%, respectively.
Further studies are required to deter-
mine whether SP1 is truly being assayed
and the significance of the "SP, raised
levels" detected in patients with breast
cancer iusing antisera capable of dis-
criminating between the various forms of
this protein (Teisner et al., 1978; Towler
et al., 1978).
MIeanwhile it seems clear that the
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measurement of circulating hPL and SP1
is of no clinical use in the management
of breast cancer patients.
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